158985-36-5

Basic information

• Product Name: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine
• Synonyms: TERT-BUTYL 4-[4-(METHOXYCARBONYL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;1-BOC-4-(4-METHOXYCARBONYLPHENYL)PIPERAZINE;4-(4-METHOXYCARBOXYPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;4-[4-(METHOXYCARBONYL)PHENYL]-1-PIPERAZINECARBOXYLIC ACID, 1,1-DIMETHYLETHYL ESTER;METHYL 4-(BOC-PIPERAZIN-1-YL)-BENZOATE;BUTTPARK 99\06-01;tert-Butyl 4-[4-(methoxycarbonyl)phenyl]piperazine-1-carboxylate;1-BOC-4-(4-METHOXYCARBONYLPHENYL)PIPERA&
• CAS NO: 158985-36-5
• Molecular Formula: C₁₇H₂₄N₂O₄
• Molecular Weight: 320.38
• Product Categories: API intermediates;piperazines;Building Blocks;C16 to C29;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 158985-36-5.mol
• Article Data: 14

Chemical Properties

• Melting Point: 166-170 °C(lit.)
• Boiling Point: 451.7°Cat760mmHg
• Flash Point: 227°C
• Appearance: /
• Density: 1.153g/cm³
• Vapor Pressure: 2.38E-08mmHg at 25°C
• Refractive Index: 1.535
• CAS DataBase Reference: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(158985-36-5)
• EPA Substance Registry System: 1-Boc-4-(4-methoxycarbonylphenyl)piperazine(158985-36-5)

Safety Data

• Hazard Codes: T
• Statements: 25-52/53
• Safety Statements: 45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 2
• Hazardous Substances Data: 158985-36-5(Hazardous Substances Data)

Usage

General Description

1-Boc-4-(4-methoxycarbonylphenyl)piperazine is a chemical compound with the molecular formula C18H26N2O4. It is a derivative of piperazine and contains a 4-(4-methoxycarbonylphenyl) moiety attached to the piperazine ring. The compound has a tert-butoxycarbonyl (Boc) protecting group on the nitrogen atom of the piperazine ring. 1-Boc-4-(4-methoxycarbonylphenyl)piperazine is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It may also have potential applications in medicinal chemistry and drug development due to its structural features and pharmacological properties.

InChI:InChI=1/C17H24N2O4/c1-17(2,3)23-16(21)19-11-9-18(10-12-19)14-7-5-13(6-8-14)15(20)22-4/h5-8H,9-12H2,1-4H3

Upstream product

• 619-44-3 methyl 4-iodobenzoate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 403-33-8 methyl 4-flurobenzoate 
• 619-45-4 4-methoxycarbonyl aniline 
• 3375-31-3 palladium diacetate 
• 163210-97-7 methyl 4-(piperazin-1-yl)benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 619-42-1 4-methoxycarbonylphenyl bromide 

Downstream Products

• 1447331-89-6 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid 
• 1447330-19-9 [1-oxo-6-(4-piperazinium-1-yl-benzoylamino)-1,3-dihydroisoindol-2-yl]acetic acid trifluoroacetate 
• 1447331-32-9 {6-[4-(4-boc-piperazin-1-yl)benzoylamino]-1-oxo-1,3-dihydroisoindol-2-yl}acetic acid methyl ester 
• 1092480-46-0 C₂₇H₂₆Cl₂N₆O₂ 
• 1092480-21-1 C₂₃H₂₆Cl₂N₆O 
• 1092481-73-6 C₂₅H₃₂N₄O₄ 
• 1092481-78-1 C₂₄H₃₀N₄O₄ 
• 1092481-71-4 C₂₅H₃₁N₅O₃ 
• 1092481-74-7 C₂₅H₃₀N₄O₃ 
• 1092481-79-2 C₂₄H₂₈N₄O₃ 
• 1092481-53-2 C₂₁H₃₁N₅O₂ 
• 1092481-75-8 C₂₀H₂₂N₄O 

Relevant articles and documents

ROR [gamma]t inhibitor, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to an ROR [gamma]t inhibitor, a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound, a method for preparing the pharmaceutical composition, and application of the compound or the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST

Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.